nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCB1—kidney cancer	0.116	1	CbGaD
Buprenorphine—CYP3A7—Temsirolimus—kidney cancer	0.0341	0.0543	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0341	0.0543	CbGbCtD
Buprenorphine—UGT1A9—Sorafenib—kidney cancer	0.0313	0.0498	CbGbCtD
Buprenorphine—CYP3A5—Temsirolimus—kidney cancer	0.0256	0.0407	CbGbCtD
Buprenorphine—ABCG2—Pazopanib—kidney cancer	0.0243	0.0386	CbGbCtD
Buprenorphine—ABCG2—Dactinomycin—kidney cancer	0.0222	0.0353	CbGbCtD
Buprenorphine—ABCG2—Erlotinib—kidney cancer	0.0173	0.0276	CbGbCtD
Buprenorphine—ABCB1—Temsirolimus—kidney cancer	0.0167	0.0265	CbGbCtD
Buprenorphine—ABCG2—Paclitaxel—kidney cancer	0.0159	0.0252	CbGbCtD
Buprenorphine—CYP2D6—Temsirolimus—kidney cancer	0.0157	0.025	CbGbCtD
Buprenorphine—CYP3A4—Everolimus—kidney cancer	0.0148	0.0235	CbGbCtD
Buprenorphine—ABCG2—Sorafenib—kidney cancer	0.0141	0.0224	CbGbCtD
Buprenorphine—ABCG2—Vincristine—kidney cancer	0.0137	0.0218	CbGbCtD
Buprenorphine—CYP2C8—Pazopanib—kidney cancer	0.0129	0.0206	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0117	0.0186	CbGbCtD
Buprenorphine—CYP3A7—Paclitaxel—kidney cancer	0.0117	0.0186	CbGbCtD
Buprenorphine—ABCG2—Sunitinib—kidney cancer	0.0114	0.0182	CbGbCtD
Buprenorphine—CYP3A7—Sorafenib—kidney cancer	0.0104	0.0166	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0104	0.0166	CbGbCtD
Buprenorphine—CYP3A7—Vincristine—kidney cancer	0.0101	0.0161	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0101	0.0161	CbGbCtD
Buprenorphine—CYP1A2—Pazopanib—kidney cancer	0.01	0.0159	CbGbCtD
Buprenorphine—CYP3A4—Temsirolimus—kidney cancer	0.00999	0.0159	CbGbCtD
Buprenorphine—CYP3A5—Erlotinib—kidney cancer	0.0096	0.0153	CbGbCtD
Buprenorphine—CYP2C9—Capecitabine—kidney cancer	0.00941	0.015	CbGbCtD
Buprenorphine—CYP2C8—Erlotinib—kidney cancer	0.00923	0.0147	CbGbCtD
Buprenorphine—CYP3A5—Paclitaxel—kidney cancer	0.00879	0.014	CbGbCtD
Buprenorphine—ABCB1—Pazopanib—kidney cancer	0.00876	0.0139	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—kidney cancer	0.00855	0.0136	CbGbCtD
Buprenorphine—CYP2C8—Paclitaxel—kidney cancer	0.00845	0.0134	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.00843	0.0134	CbGbCtD
Buprenorphine—CYP3A7—Sunitinib—kidney cancer	0.00843	0.0134	CbGbCtD
Buprenorphine—CYP2D6—Pazopanib—kidney cancer	0.00825	0.0131	CbGbCtD
Buprenorphine—ABCB1—Dactinomycin—kidney cancer	0.00801	0.0127	CbGbCtD
Buprenorphine—CYP3A5—Sorafenib—kidney cancer	0.00781	0.0124	CbGbCtD
Buprenorphine—CYP3A5—Vincristine—kidney cancer	0.00758	0.0121	CbGbCtD
Buprenorphine—CYP2C8—Sorafenib—kidney cancer	0.00751	0.0119	CbGbCtD
Buprenorphine—CYP1A2—Erlotinib—kidney cancer	0.00715	0.0114	CbGbCtD
Buprenorphine—ABCB1—Gemcitabine—kidney cancer	0.00633	0.0101	CbGbCtD
Buprenorphine—CYP3A5—Sunitinib—kidney cancer	0.00633	0.0101	CbGbCtD
Buprenorphine—CYP2C19—Sorafenib—kidney cancer	0.0063	0.01	CbGbCtD
Buprenorphine—ABCB1—Erlotinib—kidney cancer	0.00625	0.00994	CbGbCtD
Buprenorphine—CYP2C9—Paclitaxel—kidney cancer	0.00589	0.00937	CbGbCtD
Buprenorphine—CYP2D6—Erlotinib—kidney cancer	0.00589	0.00936	CbGbCtD
Buprenorphine—CYP1A2—Sorafenib—kidney cancer	0.00581	0.00924	CbGbCtD
Buprenorphine—ABCB1—Paclitaxel—kidney cancer	0.00572	0.0091	CbGbCtD
Buprenorphine—CYP3A4—Pazopanib—kidney cancer	0.00525	0.00835	CbGbCtD
Buprenorphine—CYP2C9—Sorafenib—kidney cancer	0.00524	0.00833	CbGbCtD
Buprenorphine—ABCB1—Sorafenib—kidney cancer	0.00508	0.00808	CbGbCtD
Buprenorphine—ABCB1—Vinblastine—kidney cancer	0.00502	0.00798	CbGbCtD
Buprenorphine—ABCB1—Vincristine—kidney cancer	0.00493	0.00785	CbGbCtD
Buprenorphine—CYP2D6—Sorafenib—kidney cancer	0.00479	0.00761	CbGbCtD
Buprenorphine—CYP2D6—Vinblastine—kidney cancer	0.00473	0.00752	CbGbCtD
Buprenorphine—ABCB1—Sunitinib—kidney cancer	0.00412	0.00655	CbGbCtD
Buprenorphine—CYP3A4—Erlotinib—kidney cancer	0.00374	0.00595	CbGbCtD
Buprenorphine—CYP3A4—Paclitaxel—kidney cancer	0.00343	0.00545	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—kidney cancer	0.00308	0.0049	CbGbCtD
Buprenorphine—CYP3A4—Sorafenib—kidney cancer	0.00304	0.00484	CbGbCtD
Buprenorphine—CYP3A4—Vinblastine—kidney cancer	0.00301	0.00478	CbGbCtD
Buprenorphine—CYP3A4—Vincristine—kidney cancer	0.00296	0.0047	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—kidney cancer	0.0029	0.00462	CbGbCtD
Buprenorphine—CYP3A4—Sunitinib—kidney cancer	0.00247	0.00392	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—kidney cancer	0.00185	0.00294	CbGbCtD
Buprenorphine—CYP2C19—urine—kidney cancer	0.00173	0.103	CbGeAlD
Buprenorphine—CYP1A2—urine—kidney cancer	0.00141	0.084	CbGeAlD
Buprenorphine—CYP2C9—urine—kidney cancer	0.00134	0.0797	CbGeAlD
Buprenorphine—UGT1A9—renal system—kidney cancer	0.00114	0.0677	CbGeAlD
Buprenorphine—UGT1A9—kidney—kidney cancer	0.0011	0.0655	CbGeAlD
Buprenorphine—CYP3A4—urine—kidney cancer	0.00102	0.0608	CbGeAlD
Buprenorphine—CYP2D6—urine—kidney cancer	0.001	0.0598	CbGeAlD
Buprenorphine—OPRD1—renal system—kidney cancer	0.000899	0.0535	CbGeAlD
Buprenorphine—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000885	0.0527	CbGeAlD
Buprenorphine—OPRD1—kidney—kidney cancer	0.000869	0.0518	CbGeAlD
Buprenorphine—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.000757	0.0451	CbGeAlD
Buprenorphine—ABCG2—nephron tubule—kidney cancer	0.000394	0.0235	CbGeAlD
Buprenorphine—CYP2C8—renal system—kidney cancer	0.000369	0.022	CbGeAlD
Buprenorphine—CYP3A5—nephron tubule—kidney cancer	0.000366	0.0218	CbGeAlD
Buprenorphine—CYP2C8—kidney—kidney cancer	0.000357	0.0212	CbGeAlD
Buprenorphine—CYP1A2—renal system—kidney cancer	0.000345	0.0206	CbGeAlD
Buprenorphine—CYP3A5—renal system—kidney cancer	0.000333	0.0198	CbGeAlD
Buprenorphine—CYP3A5—kidney—kidney cancer	0.000322	0.0192	CbGeAlD
Buprenorphine—CYP3A5—cortex of kidney—kidney cancer	0.000313	0.0187	CbGeAlD
Buprenorphine—CYP3A4—renal system—kidney cancer	0.00025	0.0149	CbGeAlD
Buprenorphine—CYP2D6—renal system—kidney cancer	0.000246	0.0146	CbGeAlD
Buprenorphine—CYP3A4—kidney—kidney cancer	0.000242	0.0144	CbGeAlD
Buprenorphine—CYP2D6—kidney—kidney cancer	0.000238	0.0142	CbGeAlD
Buprenorphine—ABCB1—nephron tubule—kidney cancer	0.000195	0.0116	CbGeAlD
Buprenorphine—ABCB1—renal system—kidney cancer	0.000177	0.0105	CbGeAlD
Buprenorphine—ABCB1—kidney—kidney cancer	0.000171	0.0102	CbGeAlD
Buprenorphine—ABCB1—cortex of kidney—kidney cancer	0.000166	0.00991	CbGeAlD
Buprenorphine—ABCB1—gonad—kidney cancer	0.000159	0.00944	CbGeAlD
Buprenorphine—Chills—Capecitabine—kidney cancer	8.3e-05	0.000462	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.29e-05	0.000462	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.25e-05	0.00046	CcSEcCtD
Buprenorphine—Discomfort—Paclitaxel—kidney cancer	8.25e-05	0.00046	CcSEcCtD
Buprenorphine—Fatigue—Gemcitabine—kidney cancer	8.24e-05	0.000459	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Vincristine—kidney cancer	8.24e-05	0.000459	CcSEcCtD
Buprenorphine—Dizziness—Sorafenib—kidney cancer	8.19e-05	0.000456	CcSEcCtD
Buprenorphine—Pain—Gemcitabine—kidney cancer	8.18e-05	0.000455	CcSEcCtD
Buprenorphine—Constipation—Gemcitabine—kidney cancer	8.18e-05	0.000455	CcSEcCtD
Buprenorphine—Nausea—Erlotinib—kidney cancer	8.18e-05	0.000455	CcSEcCtD
Buprenorphine—Dry mouth—Paclitaxel—kidney cancer	8.17e-05	0.000455	CcSEcCtD
Buprenorphine—Mood swings—Doxorubicin—kidney cancer	8.16e-05	0.000455	CcSEcCtD
Buprenorphine—Diarrhoea—Sunitinib—kidney cancer	8.15e-05	0.000454	CcSEcCtD
Buprenorphine—Mental disorder—Capecitabine—kidney cancer	8.1e-05	0.000451	CcSEcCtD
Buprenorphine—Asthenia—Dactinomycin—kidney cancer	8.09e-05	0.000451	CcSEcCtD
Buprenorphine—Confusional state—Paclitaxel—kidney cancer	8.07e-05	0.00045	CcSEcCtD
Buprenorphine—Erythema—Capecitabine—kidney cancer	8.05e-05	0.000448	CcSEcCtD
Buprenorphine—Malnutrition—Capecitabine—kidney cancer	8.05e-05	0.000448	CcSEcCtD
Buprenorphine—Dehydration—Doxorubicin—kidney cancer	8.01e-05	0.000446	CcSEcCtD
Buprenorphine—Oedema—Paclitaxel—kidney cancer	8.01e-05	0.000446	CcSEcCtD
Buprenorphine—Anaphylactic shock—Paclitaxel—kidney cancer	8.01e-05	0.000446	CcSEcCtD
Buprenorphine—Abdominal pain—Vincristine—kidney cancer	7.97e-05	0.000444	CcSEcCtD
Buprenorphine—Body temperature increased—Vincristine—kidney cancer	7.97e-05	0.000444	CcSEcCtD
Buprenorphine—Infection—Paclitaxel—kidney cancer	7.95e-05	0.000443	CcSEcCtD
Buprenorphine—Flatulence—Capecitabine—kidney cancer	7.93e-05	0.000442	CcSEcCtD
Buprenorphine—Dry skin—Doxorubicin—kidney cancer	7.9e-05	0.00044	CcSEcCtD
Buprenorphine—Dysgeusia—Capecitabine—kidney cancer	7.88e-05	0.000439	CcSEcCtD
Buprenorphine—Dizziness—Sunitinib—kidney cancer	7.88e-05	0.000439	CcSEcCtD
Buprenorphine—Feeling abnormal—Gemcitabine—kidney cancer	7.88e-05	0.000439	CcSEcCtD
Buprenorphine—Shock—Paclitaxel—kidney cancer	7.88e-05	0.000439	CcSEcCtD
Buprenorphine—Vomiting—Sorafenib—kidney cancer	7.87e-05	0.000439	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Doxorubicin—kidney cancer	7.87e-05	0.000438	CcSEcCtD
Buprenorphine—Abdominal pain upper—Doxorubicin—kidney cancer	7.87e-05	0.000438	CcSEcCtD
Buprenorphine—Nervous system disorder—Paclitaxel—kidney cancer	7.85e-05	0.000437	CcSEcCtD
Buprenorphine—Tachycardia—Paclitaxel—kidney cancer	7.81e-05	0.000435	CcSEcCtD
Buprenorphine—Rash—Sorafenib—kidney cancer	7.81e-05	0.000435	CcSEcCtD
Buprenorphine—Dermatitis—Sorafenib—kidney cancer	7.8e-05	0.000434	CcSEcCtD
Buprenorphine—Back pain—Capecitabine—kidney cancer	7.79e-05	0.000434	CcSEcCtD
Buprenorphine—Breast disorder—Doxorubicin—kidney cancer	7.79e-05	0.000434	CcSEcCtD
Buprenorphine—Skin disorder—Paclitaxel—kidney cancer	7.78e-05	0.000433	CcSEcCtD
Buprenorphine—Headache—Sorafenib—kidney cancer	7.76e-05	0.000432	CcSEcCtD
Buprenorphine—Muscle spasms—Capecitabine—kidney cancer	7.74e-05	0.000431	CcSEcCtD
Buprenorphine—Hyperhidrosis—Paclitaxel—kidney cancer	7.74e-05	0.000431	CcSEcCtD
Buprenorphine—Diarrhoea—Dactinomycin—kidney cancer	7.72e-05	0.00043	CcSEcCtD
Buprenorphine—Nasopharyngitis—Doxorubicin—kidney cancer	7.7e-05	0.000429	CcSEcCtD
Buprenorphine—Anorexia—Paclitaxel—kidney cancer	7.63e-05	0.000425	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Doxorubicin—kidney cancer	7.6e-05	0.000423	CcSEcCtD
Buprenorphine—Muscular weakness—Doxorubicin—kidney cancer	7.6e-05	0.000423	CcSEcCtD
Buprenorphine—Vision blurred—Capecitabine—kidney cancer	7.59e-05	0.000423	CcSEcCtD
Buprenorphine—Vomiting—Sunitinib—kidney cancer	7.58e-05	0.000422	CcSEcCtD
Buprenorphine—Body temperature increased—Gemcitabine—kidney cancer	7.56e-05	0.000421	CcSEcCtD
Buprenorphine—Tremor—Capecitabine—kidney cancer	7.54e-05	0.00042	CcSEcCtD
Buprenorphine—Rash—Sunitinib—kidney cancer	7.51e-05	0.000418	CcSEcCtD
Buprenorphine—Dermatitis—Sunitinib—kidney cancer	7.51e-05	0.000418	CcSEcCtD
Buprenorphine—Abdominal distension—Doxorubicin—kidney cancer	7.5e-05	0.000418	CcSEcCtD
Buprenorphine—Hypotension—Paclitaxel—kidney cancer	7.48e-05	0.000417	CcSEcCtD
Buprenorphine—Ill-defined disorder—Capecitabine—kidney cancer	7.47e-05	0.000416	CcSEcCtD
Buprenorphine—Headache—Sunitinib—kidney cancer	7.46e-05	0.000416	CcSEcCtD
Buprenorphine—Asthma—Doxorubicin—kidney cancer	7.45e-05	0.000415	CcSEcCtD
Buprenorphine—Influenza—Doxorubicin—kidney cancer	7.45e-05	0.000415	CcSEcCtD
Buprenorphine—Dysphagia—Doxorubicin—kidney cancer	7.45e-05	0.000415	CcSEcCtD
Buprenorphine—Hypersensitivity—Vincristine—kidney cancer	7.43e-05	0.000414	CcSEcCtD
Buprenorphine—Nausea—Sorafenib—kidney cancer	7.36e-05	0.00041	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.29e-05	0.000406	CcSEcCtD
Buprenorphine—Malaise—Capecitabine—kidney cancer	7.26e-05	0.000404	CcSEcCtD
Buprenorphine—Angina pectoris—Doxorubicin—kidney cancer	7.25e-05	0.000404	CcSEcCtD
Buprenorphine—Insomnia—Paclitaxel—kidney cancer	7.24e-05	0.000403	CcSEcCtD
Buprenorphine—Vertigo—Capecitabine—kidney cancer	7.23e-05	0.000403	CcSEcCtD
Buprenorphine—Asthenia—Vincristine—kidney cancer	7.23e-05	0.000403	CcSEcCtD
Buprenorphine—Syncope—Capecitabine—kidney cancer	7.22e-05	0.000402	CcSEcCtD
Buprenorphine—Paraesthesia—Paclitaxel—kidney cancer	7.19e-05	0.0004	CcSEcCtD
Buprenorphine—Vomiting—Dactinomycin—kidney cancer	7.17e-05	0.000399	CcSEcCtD
Buprenorphine—Bronchitis—Doxorubicin—kidney cancer	7.16e-05	0.000399	CcSEcCtD
Buprenorphine—Dyspnoea—Paclitaxel—kidney cancer	7.14e-05	0.000397	CcSEcCtD
Buprenorphine—Somnolence—Paclitaxel—kidney cancer	7.12e-05	0.000396	CcSEcCtD
Buprenorphine—Palpitations—Capecitabine—kidney cancer	7.11e-05	0.000396	CcSEcCtD
Buprenorphine—Rash—Dactinomycin—kidney cancer	7.11e-05	0.000396	CcSEcCtD
Buprenorphine—Nausea—Sunitinib—kidney cancer	7.08e-05	0.000394	CcSEcCtD
Buprenorphine—Loss of consciousness—Capecitabine—kidney cancer	7.07e-05	0.000394	CcSEcCtD
Buprenorphine—Dyspepsia—Paclitaxel—kidney cancer	7.05e-05	0.000392	CcSEcCtD
Buprenorphine—Cough—Capecitabine—kidney cancer	7.02e-05	0.000391	CcSEcCtD
Buprenorphine—Decreased appetite—Paclitaxel—kidney cancer	6.96e-05	0.000388	CcSEcCtD
Buprenorphine—Hypertension—Capecitabine—kidney cancer	6.95e-05	0.000387	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.92e-05	0.000385	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.91e-05	0.000385	CcSEcCtD
Buprenorphine—Fatigue—Paclitaxel—kidney cancer	6.9e-05	0.000384	CcSEcCtD
Buprenorphine—Diarrhoea—Vincristine—kidney cancer	6.9e-05	0.000384	CcSEcCtD
Buprenorphine—Asthenia—Gemcitabine—kidney cancer	6.86e-05	0.000382	CcSEcCtD
Buprenorphine—Arthralgia—Capecitabine—kidney cancer	6.85e-05	0.000382	CcSEcCtD
Buprenorphine—Chest pain—Capecitabine—kidney cancer	6.85e-05	0.000382	CcSEcCtD
Buprenorphine—Myalgia—Capecitabine—kidney cancer	6.85e-05	0.000382	CcSEcCtD
Buprenorphine—Pain—Paclitaxel—kidney cancer	6.85e-05	0.000381	CcSEcCtD
Buprenorphine—Constipation—Paclitaxel—kidney cancer	6.85e-05	0.000381	CcSEcCtD
Buprenorphine—Anxiety—Capecitabine—kidney cancer	6.83e-05	0.00038	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.81e-05	0.000379	CcSEcCtD
Buprenorphine—Discomfort—Capecitabine—kidney cancer	6.77e-05	0.000377	CcSEcCtD
Buprenorphine—Pruritus—Gemcitabine—kidney cancer	6.76e-05	0.000377	CcSEcCtD
Buprenorphine—Weight decreased—Doxorubicin—kidney cancer	6.74e-05	0.000375	CcSEcCtD
Buprenorphine—Dry mouth—Capecitabine—kidney cancer	6.7e-05	0.000373	CcSEcCtD
Buprenorphine—Nausea—Dactinomycin—kidney cancer	6.7e-05	0.000373	CcSEcCtD
Buprenorphine—Dizziness—Vincristine—kidney cancer	6.66e-05	0.000371	CcSEcCtD
Buprenorphine—Infestation NOS—Doxorubicin—kidney cancer	6.64e-05	0.00037	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—kidney cancer	6.64e-05	0.00037	CcSEcCtD
Buprenorphine—Confusional state—Capecitabine—kidney cancer	6.62e-05	0.000369	CcSEcCtD
Buprenorphine—Feeling abnormal—Paclitaxel—kidney cancer	6.6e-05	0.000367	CcSEcCtD
Buprenorphine—Oedema—Capecitabine—kidney cancer	6.57e-05	0.000366	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Paclitaxel—kidney cancer	6.55e-05	0.000365	CcSEcCtD
Buprenorphine—Diarrhoea—Gemcitabine—kidney cancer	6.54e-05	0.000364	CcSEcCtD
Buprenorphine—Infection—Capecitabine—kidney cancer	6.53e-05	0.000363	CcSEcCtD
Buprenorphine—Shock—Capecitabine—kidney cancer	6.46e-05	0.00036	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—kidney cancer	6.45e-05	0.000359	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—kidney cancer	6.45e-05	0.000359	CcSEcCtD
Buprenorphine—Nervous system disorder—Capecitabine—kidney cancer	6.44e-05	0.000359	CcSEcCtD
Buprenorphine—Tachycardia—Capecitabine—kidney cancer	6.41e-05	0.000357	CcSEcCtD
Buprenorphine—Vomiting—Vincristine—kidney cancer	6.41e-05	0.000357	CcSEcCtD
Buprenorphine—Skin disorder—Capecitabine—kidney cancer	6.38e-05	0.000355	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—kidney cancer	6.37e-05	0.000355	CcSEcCtD
Buprenorphine—Urticaria—Paclitaxel—kidney cancer	6.36e-05	0.000354	CcSEcCtD
Buprenorphine—Rash—Vincristine—kidney cancer	6.35e-05	0.000354	CcSEcCtD
Buprenorphine—Hyperhidrosis—Capecitabine—kidney cancer	6.35e-05	0.000354	CcSEcCtD
Buprenorphine—Dermatitis—Vincristine—kidney cancer	6.35e-05	0.000354	CcSEcCtD
Buprenorphine—Abdominal pain—Paclitaxel—kidney cancer	6.33e-05	0.000352	CcSEcCtD
Buprenorphine—Body temperature increased—Paclitaxel—kidney cancer	6.33e-05	0.000352	CcSEcCtD
Buprenorphine—Headache—Vincristine—kidney cancer	6.31e-05	0.000352	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—kidney cancer	6.28e-05	0.00035	CcSEcCtD
Buprenorphine—Anorexia—Capecitabine—kidney cancer	6.26e-05	0.000349	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—kidney cancer	6.23e-05	0.000347	CcSEcCtD
Buprenorphine—Hypotension—Capecitabine—kidney cancer	6.14e-05	0.000342	CcSEcCtD
Buprenorphine—Vomiting—Gemcitabine—kidney cancer	6.08e-05	0.000339	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—kidney cancer	6.07e-05	0.000338	CcSEcCtD
Buprenorphine—Rash—Gemcitabine—kidney cancer	6.03e-05	0.000336	CcSEcCtD
Buprenorphine—Dermatitis—Gemcitabine—kidney cancer	6.02e-05	0.000335	CcSEcCtD
Buprenorphine—Headache—Gemcitabine—kidney cancer	5.99e-05	0.000334	CcSEcCtD
Buprenorphine—Nausea—Vincristine—kidney cancer	5.99e-05	0.000333	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.99e-05	0.000333	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—kidney cancer	5.98e-05	0.000333	CcSEcCtD
Buprenorphine—Insomnia—Capecitabine—kidney cancer	5.94e-05	0.000331	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—kidney cancer	5.93e-05	0.00033	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—kidney cancer	5.92e-05	0.000329	CcSEcCtD
Buprenorphine—Paraesthesia—Capecitabine—kidney cancer	5.9e-05	0.000329	CcSEcCtD
Buprenorphine—Hypersensitivity—Paclitaxel—kidney cancer	5.9e-05	0.000328	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—kidney cancer	5.89e-05	0.000328	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—kidney cancer	5.87e-05	0.000327	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—kidney cancer	5.86e-05	0.000326	CcSEcCtD
Buprenorphine—Dyspnoea—Capecitabine—kidney cancer	5.86e-05	0.000326	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—kidney cancer	5.84e-05	0.000325	CcSEcCtD
Buprenorphine—Dyspepsia—Capecitabine—kidney cancer	5.78e-05	0.000322	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—kidney cancer	5.74e-05	0.00032	CcSEcCtD
Buprenorphine—Asthenia—Paclitaxel—kidney cancer	5.74e-05	0.00032	CcSEcCtD
Buprenorphine—Decreased appetite—Capecitabine—kidney cancer	5.71e-05	0.000318	CcSEcCtD
Buprenorphine—Nausea—Gemcitabine—kidney cancer	5.68e-05	0.000316	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Capecitabine—kidney cancer	5.67e-05	0.000316	CcSEcCtD
Buprenorphine—Fatigue—Capecitabine—kidney cancer	5.66e-05	0.000315	CcSEcCtD
Buprenorphine—Pruritus—Paclitaxel—kidney cancer	5.66e-05	0.000315	CcSEcCtD
Buprenorphine—Constipation—Capecitabine—kidney cancer	5.62e-05	0.000313	CcSEcCtD
Buprenorphine—Pain—Capecitabine—kidney cancer	5.62e-05	0.000313	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—kidney cancer	5.57e-05	0.00031	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—kidney cancer	5.56e-05	0.00031	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—kidney cancer	5.53e-05	0.000308	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—kidney cancer	5.53e-05	0.000308	CcSEcCtD
Buprenorphine—Diarrhoea—Paclitaxel—kidney cancer	5.48e-05	0.000305	CcSEcCtD
Buprenorphine—Feeling abnormal—Capecitabine—kidney cancer	5.41e-05	0.000302	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—kidney cancer	5.41e-05	0.000301	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—kidney cancer	5.38e-05	0.0003	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Capecitabine—kidney cancer	5.37e-05	0.000299	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—kidney cancer	5.37e-05	0.000299	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—kidney cancer	5.35e-05	0.000298	CcSEcCtD
Buprenorphine—Dizziness—Paclitaxel—kidney cancer	5.29e-05	0.000295	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—kidney cancer	5.22e-05	0.000291	CcSEcCtD
Buprenorphine—Urticaria—Capecitabine—kidney cancer	5.22e-05	0.000291	CcSEcCtD
Buprenorphine—Abdominal pain—Capecitabine—kidney cancer	5.19e-05	0.000289	CcSEcCtD
Buprenorphine—Body temperature increased—Capecitabine—kidney cancer	5.19e-05	0.000289	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—kidney cancer	5.19e-05	0.000289	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—kidney cancer	5.19e-05	0.000289	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—kidney cancer	5.11e-05	0.000285	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—kidney cancer	5.09e-05	0.000284	CcSEcCtD
Buprenorphine—Vomiting—Paclitaxel—kidney cancer	5.09e-05	0.000283	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—kidney cancer	5.08e-05	0.000283	CcSEcCtD
Buprenorphine—Rash—Paclitaxel—kidney cancer	5.05e-05	0.000281	CcSEcCtD
Buprenorphine—Dermatitis—Paclitaxel—kidney cancer	5.04e-05	0.000281	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—kidney cancer	5.04e-05	0.000281	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—kidney cancer	5.02e-05	0.00028	CcSEcCtD
Buprenorphine—Headache—Paclitaxel—kidney cancer	5.01e-05	0.000279	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—kidney cancer	4.99e-05	0.000278	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—kidney cancer	4.89e-05	0.000272	CcSEcCtD
Buprenorphine—Hypersensitivity—Capecitabine—kidney cancer	4.84e-05	0.00027	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—kidney cancer	4.81e-05	0.000268	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—kidney cancer	4.77e-05	0.000266	CcSEcCtD
Buprenorphine—Nausea—Paclitaxel—kidney cancer	4.75e-05	0.000265	CcSEcCtD
Buprenorphine—Asthenia—Capecitabine—kidney cancer	4.71e-05	0.000263	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—kidney cancer	4.68e-05	0.000261	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—kidney cancer	4.66e-05	0.00026	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—kidney cancer	4.65e-05	0.000259	CcSEcCtD
Buprenorphine—Pruritus—Capecitabine—kidney cancer	4.65e-05	0.000259	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—kidney cancer	4.59e-05	0.000255	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—kidney cancer	4.56e-05	0.000254	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—kidney cancer	4.53e-05	0.000252	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—kidney cancer	4.5e-05	0.00025	CcSEcCtD
Buprenorphine—Diarrhoea—Capecitabine—kidney cancer	4.49e-05	0.00025	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—kidney cancer	4.48e-05	0.00025	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—kidney cancer	4.42e-05	0.000246	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—kidney cancer	4.42e-05	0.000246	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—kidney cancer	4.42e-05	0.000246	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—kidney cancer	4.4e-05	0.000245	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.39e-05	0.000244	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—kidney cancer	4.36e-05	0.000243	CcSEcCtD
Buprenorphine—Dizziness—Capecitabine—kidney cancer	4.34e-05	0.000242	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—kidney cancer	4.32e-05	0.000241	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—kidney cancer	4.27e-05	0.000238	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—kidney cancer	4.23e-05	0.000236	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—kidney cancer	4.23e-05	0.000236	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—kidney cancer	4.21e-05	0.000234	CcSEcCtD
Buprenorphine—Vomiting—Capecitabine—kidney cancer	4.18e-05	0.000233	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—kidney cancer	4.17e-05	0.000232	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—kidney cancer	4.15e-05	0.000231	CcSEcCtD
Buprenorphine—Rash—Capecitabine—kidney cancer	4.14e-05	0.000231	CcSEcCtD
Buprenorphine—Dermatitis—Capecitabine—kidney cancer	4.14e-05	0.00023	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—kidney cancer	4.13e-05	0.00023	CcSEcCtD
Buprenorphine—Headache—Capecitabine—kidney cancer	4.12e-05	0.000229	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—kidney cancer	4.11e-05	0.000229	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—kidney cancer	4.09e-05	0.000228	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—kidney cancer	4.04e-05	0.000225	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—kidney cancer	3.96e-05	0.00022	CcSEcCtD
Buprenorphine—Nausea—Capecitabine—kidney cancer	3.9e-05	0.000217	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.86e-05	0.000215	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—kidney cancer	3.83e-05	0.000213	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—kidney cancer	3.8e-05	0.000212	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—kidney cancer	3.78e-05	0.00021	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—kidney cancer	3.76e-05	0.00021	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—kidney cancer	3.73e-05	0.000208	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—kidney cancer	3.68e-05	0.000205	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.66e-05	0.000204	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—kidney cancer	3.65e-05	0.000203	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—kidney cancer	3.62e-05	0.000202	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—kidney cancer	3.62e-05	0.000202	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—kidney cancer	3.49e-05	0.000194	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—kidney cancer	3.46e-05	0.000193	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—kidney cancer	3.36e-05	0.000187	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—kidney cancer	3.35e-05	0.000186	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—kidney cancer	3.35e-05	0.000186	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—kidney cancer	3.12e-05	0.000174	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—kidney cancer	3.04e-05	0.000169	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—kidney cancer	3e-05	0.000167	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—kidney cancer	2.9e-05	0.000161	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—kidney cancer	2.8e-05	0.000156	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—kidney cancer	2.69e-05	0.00015	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—kidney cancer	2.67e-05	0.000149	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—kidney cancer	2.67e-05	0.000149	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—kidney cancer	2.65e-05	0.000148	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—kidney cancer	2.52e-05	0.00014	CcSEcCtD
Buprenorphine—ABCB1—Metabolism—ITPR2—kidney cancer	7.01e-06	0.000119	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—MAPK3—kidney cancer	6.97e-06	0.000119	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SCARB1—kidney cancer	6.95e-06	0.000118	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—POMC—kidney cancer	6.92e-06	0.000118	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KDR—kidney cancer	6.92e-06	0.000118	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.92e-06	0.000118	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.91e-06	0.000118	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS1—kidney cancer	6.88e-06	0.000117	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.86e-06	0.000117	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GSTM1—kidney cancer	6.84e-06	0.000117	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—BRAF—kidney cancer	6.84e-06	0.000116	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PSMD7—kidney cancer	6.74e-06	0.000115	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.7e-06	0.000114	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—MAPK1—kidney cancer	6.63e-06	0.000113	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.62e-06	0.000113	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ITPR2—kidney cancer	6.61e-06	0.000113	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTT1—kidney cancer	6.55e-06	0.000112	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ACHE—kidney cancer	6.55e-06	0.000112	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ITPR2—kidney cancer	6.55e-06	0.000112	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CYP1A1—kidney cancer	6.49e-06	0.000111	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PGK1—kidney cancer	6.43e-06	0.000109	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.43e-06	0.000109	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL2—kidney cancer	6.42e-06	0.000109	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTT1—kidney cancer	6.39e-06	0.000109	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ACHE—kidney cancer	6.39e-06	0.000109	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—BCHE—kidney cancer	6.39e-06	0.000109	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—APC—kidney cancer	6.38e-06	0.000109	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KIT—kidney cancer	6.38e-06	0.000109	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—PIK3CA—kidney cancer	6.33e-06	0.000108	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—kidney cancer	6.33e-06	0.000108	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SLC5A5—kidney cancer	6.32e-06	0.000108	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LDHB—kidney cancer	6.3e-06	0.000107	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—POMC—kidney cancer	6.28e-06	0.000107	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—KRAS—kidney cancer	6.26e-06	0.000107	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SCARB1—kidney cancer	6.2e-06	0.000106	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS1—kidney cancer	6.14e-06	0.000105	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HIF1A—kidney cancer	6.12e-06	0.000104	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—MAPK3—kidney cancer	6.11e-06	0.000104	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TSC2—kidney cancer	6.1e-06	0.000104	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SLC2A1—kidney cancer	6.1e-06	0.000104	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—POMC—kidney cancer	6.07e-06	0.000103	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SCARB1—kidney cancer	6.05e-06	0.000103	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.04e-06	0.000103	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTT1—kidney cancer	6.03e-06	0.000103	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ACHE—kidney cancer	6.03e-06	0.000103	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CRABP1—kidney cancer	6.02e-06	0.000103	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PSMD7—kidney cancer	6.02e-06	0.000103	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—BRAF—kidney cancer	6e-06	0.000102	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS1—kidney cancer	5.99e-06	0.000102	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTT1—kidney cancer	5.97e-06	0.000102	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ACHE—kidney cancer	5.97e-06	0.000102	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.92e-06	0.000101	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PSMD7—kidney cancer	5.88e-06	0.0001	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTP1—kidney cancer	5.87e-06	0.0001	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KDR—kidney cancer	5.85e-06	9.97e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—MAPK1—kidney cancer	5.81e-06	9.9e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—kidney cancer	5.75e-06	9.8e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RAF1—kidney cancer	5.71e-06	9.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—BCHE—kidney cancer	5.71e-06	9.72e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SCARB1—kidney cancer	5.7e-06	9.71e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RELA—kidney cancer	5.68e-06	9.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SCARB1—kidney cancer	5.65e-06	9.63e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—kidney cancer	5.65e-06	9.62e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS1—kidney cancer	5.65e-06	9.62e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SLC5A5—kidney cancer	5.64e-06	9.6e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ITPR2—kidney cancer	5.6e-06	9.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS1—kidney cancer	5.6e-06	9.53e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MTOR—kidney cancer	5.57e-06	9.49e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—BCHE—kidney cancer	5.57e-06	9.49e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ABCB1—kidney cancer	5.56e-06	9.47e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—kidney cancer	5.55e-06	9.46e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PSMD7—kidney cancer	5.54e-06	9.43e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTEN—kidney cancer	5.52e-06	9.4e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SLC5A5—kidney cancer	5.5e-06	9.37e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—kidney cancer	5.49e-06	9.35e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PSMD7—kidney cancer	5.49e-06	9.35e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CA9—kidney cancer	5.47e-06	9.31e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SLC2A1—kidney cancer	5.44e-06	9.27e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTM1—kidney cancer	5.4e-06	9.19e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KIT—kidney cancer	5.39e-06	9.18e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APC—kidney cancer	5.39e-06	9.18e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—POMC—kidney cancer	5.32e-06	9.07e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SLC2A1—kidney cancer	5.31e-06	9.05e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.28e-06	9e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—POMC—kidney cancer	5.28e-06	8.99e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—BCHE—kidney cancer	5.25e-06	8.94e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1B—kidney cancer	5.23e-06	8.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—BCHE—kidney cancer	5.2e-06	8.86e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SLC5A5—kidney cancer	5.18e-06	8.83e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK3—kidney cancer	5.16e-06	8.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.16e-06	8.79e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.16e-06	8.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SLC5A5—kidney cancer	5.14e-06	8.75e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—POMC—kidney cancer	5.13e-06	8.74e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL2—kidney cancer	5.12e-06	8.72e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP1A1—kidney cancer	5.12e-06	8.71e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ACHE—kidney cancer	5.1e-06	8.69e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTT1—kidney cancer	5.1e-06	8.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTP1—kidney cancer	5.09e-06	8.66e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	5.07e-06	8.63e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—BRAF—kidney cancer	5.07e-06	8.63e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—kidney cancer	5.04e-06	8.59e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SLC2A1—kidney cancer	5.01e-06	8.53e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RAF1—kidney cancer	5.01e-06	8.53e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—kidney cancer	5.01e-06	8.52e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—kidney cancer	4.99e-06	8.5e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RELA—kidney cancer	4.98e-06	8.49e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—JUN—kidney cancer	4.98e-06	8.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SLC2A1—kidney cancer	4.96e-06	8.45e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—kidney cancer	4.95e-06	8.43e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CTNNB1—kidney cancer	4.94e-06	8.42e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK1—kidney cancer	4.91e-06	8.37e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MTOR—kidney cancer	4.89e-06	8.32e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—POMC—kidney cancer	4.84e-06	8.24e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SCARB1—kidney cancer	4.83e-06	8.23e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.82e-06	8.2e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTEN—kidney cancer	4.82e-06	8.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ABCB1—kidney cancer	4.82e-06	8.2e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS1—kidney cancer	4.78e-06	8.15e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—kidney cancer	4.69e-06	7.99e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PSMD7—kidney cancer	4.69e-06	7.99e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTM1—kidney cancer	4.68e-06	7.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CRABP1—kidney cancer	4.65e-06	7.91e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—kidney cancer	4.64e-06	7.9e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.61e-06	7.85e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1B—kidney cancer	4.59e-06	7.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTP1—kidney cancer	4.54e-06	7.73e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—kidney cancer	4.49e-06	7.64e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—BCHE—kidney cancer	4.45e-06	7.57e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTP1—kidney cancer	4.43e-06	7.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP1A1—kidney cancer	4.43e-06	7.55e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC5A5—kidney cancer	4.39e-06	7.48e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—kidney cancer	4.38e-06	7.45e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—JUN—kidney cancer	4.37e-06	7.44e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—kidney cancer	4.37e-06	7.43e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—kidney cancer	4.35e-06	7.41e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CTNNB1—kidney cancer	4.33e-06	7.38e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ITPR2—kidney cancer	4.32e-06	7.36e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—kidney cancer	4.3e-06	7.32e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—kidney cancer	4.26e-06	7.26e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—kidney cancer	4.25e-06	7.23e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC2A1—kidney cancer	4.24e-06	7.22e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RAF1—kidney cancer	4.23e-06	7.21e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—kidney cancer	4.22e-06	7.19e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RELA—kidney cancer	4.21e-06	7.17e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—kidney cancer	4.21e-06	7.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.2e-06	7.15e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—kidney cancer	4.19e-06	7.13e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—kidney cancer	4.18e-06	7.11e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—kidney cancer	4.17e-06	7.11e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—kidney cancer	4.14e-06	7.05e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MTOR—kidney cancer	4.13e-06	7.03e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.12e-06	7.01e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—kidney cancer	4.12e-06	7.01e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—kidney cancer	4.07e-06	6.94e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—kidney cancer	4e-06	6.82e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP1A1—kidney cancer	3.96e-06	6.74e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—kidney cancer	3.95e-06	6.73e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ACHE—kidney cancer	3.94e-06	6.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTT1—kidney cancer	3.94e-06	6.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—kidney cancer	3.92e-06	6.68e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK1—kidney cancer	3.92e-06	6.67e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—kidney cancer	3.9e-06	6.63e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1B—kidney cancer	3.88e-06	6.6e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP1A1—kidney cancer	3.86e-06	6.58e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—kidney cancer	3.86e-06	6.57e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—kidney cancer	3.84e-06	6.54e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—POMC—kidney cancer	3.81e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—kidney cancer	3.81e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—kidney cancer	3.8e-06	6.48e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—kidney cancer	3.79e-06	6.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SCARB1—kidney cancer	3.73e-06	6.35e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—kidney cancer	3.7e-06	6.31e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—kidney cancer	3.7e-06	6.3e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—kidney cancer	3.7e-06	6.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS1—kidney cancer	3.69e-06	6.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JUN—kidney cancer	3.69e-06	6.28e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—kidney cancer	3.67e-06	6.25e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—kidney cancer	3.66e-06	6.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.64e-06	6.2e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.64e-06	6.2e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PSMD7—kidney cancer	3.62e-06	6.17e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—kidney cancer	3.61e-06	6.15e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.61e-06	6.14e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.59e-06	6.11e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—kidney cancer	3.57e-06	6.08e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—kidney cancer	3.54e-06	6.03e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—kidney cancer	3.51e-06	5.98e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK1—kidney cancer	3.43e-06	5.85e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—BCHE—kidney cancer	3.43e-06	5.84e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—kidney cancer	3.4e-06	5.79e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.39e-06	5.77e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—kidney cancer	3.36e-06	5.73e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—kidney cancer	3.35e-06	5.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—POMC—kidney cancer	3.3e-06	5.63e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—kidney cancer	3.29e-06	5.6e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.27e-06	5.58e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—kidney cancer	3.25e-06	5.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.25e-06	5.53e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—kidney cancer	3.24e-06	5.52e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—kidney cancer	3.22e-06	5.49e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.08e-06	5.25e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—kidney cancer	3.08e-06	5.24e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—kidney cancer	3.05e-06	5.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—kidney cancer	3.04e-06	5.18e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—kidney cancer	2.98e-06	5.07e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—kidney cancer	2.97e-06	5.05e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.96e-06	5.05e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—POMC—kidney cancer	2.95e-06	5.02e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK1—kidney cancer	2.9e-06	4.94e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—kidney cancer	2.88e-06	4.91e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—POMC—kidney cancer	2.88e-06	4.9e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—kidney cancer	2.74e-06	4.67e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—kidney cancer	2.73e-06	4.65e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—POMC—kidney cancer	2.71e-06	4.62e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—POMC—kidney cancer	2.69e-06	4.58e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—kidney cancer	2.65e-06	4.52e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—kidney cancer	2.64e-06	4.49e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—kidney cancer	2.61e-06	4.45e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.59e-06	4.41e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—kidney cancer	2.58e-06	4.4e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.53e-06	4.31e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—kidney cancer	2.52e-06	4.29e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—kidney cancer	2.51e-06	4.27e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—kidney cancer	2.44e-06	4.15e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.38e-06	4.05e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—kidney cancer	2.37e-06	4.04e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—kidney cancer	2.35e-06	4.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—kidney cancer	2.3e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—POMC—kidney cancer	2.3e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—kidney cancer	2.3e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—kidney cancer	2.16e-06	3.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—kidney cancer	2.15e-06	3.65e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—kidney cancer	2.05e-06	3.49e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—kidney cancer	2e-06	3.41e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—kidney cancer	1.89e-06	3.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.87e-06	3.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—kidney cancer	1.87e-06	3.19e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—kidney cancer	1.83e-06	3.12e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—POMC—kidney cancer	1.77e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.62e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—kidney cancer	1.6e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.45e-06	2.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—kidney cancer	1.41e-06	2.41e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—kidney cancer	1.41e-06	2.41e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.33e-06	2.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.32e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—kidney cancer	1.23e-06	2.1e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.13e-06	1.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.7e-07	1.48e-05	CbGpPWpGaD
